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Abstract 
Inkjet printing technology was used to apply insulin polymeric layers on metal microneedles 
for transdermal delivery. A range of various polymers such as gelatin (GLN) , polyvinyl 
caprolactame-polyvinyl acetate-polyethylene glycol (SOL) , poly(2-ethyl-2-oxazoline) (POX) 
and trehalose (THL) were assessed for  their capacity to form thin uniform and homogeneous 
layers that preserve insulin intact.  Atomic force microscopy (AFM) showed homogeneous 
insulin ± polymer layers without any phase separation while SOL demonstrated the best 
SHUIRUPDQFH  &LUFXODU GLVFURLVP &' DQDO\VLV RI UHK\GUDWHG ILOPV VKRZHG WKDW LQVXOLQ¶V
alpha helices and ß±sheet were well preserved for THL and SOL. In contrast, GLN and POX 
insulin layers revealed small band shifts indicating possible conformational changes.  Insulin 
release in Franz diffusion cells from MNs inserted into porcine skin showed rapid release 
rates for POX and GLN within the first 20 min. Inkjet printing was proved an effective 
approach for transdermal delivery of insulin in solid state.  
 
1. Introduction 
Insulin medication is regarded as the most effective treatment for type 1 diabetes, with 
all type 1 and some type 2 diabetics requiring insulin injections to achieve glycaemic control 
(Hemmingsen et al, 2011). Insulin is typically given to the patient through self-administered 
subcutaneous needle injection. However, studies have found that these methods are 
inconvenient and painful, which has led to a decrease in compliance (Asche et al, 2010). It 
has been found that 1 out of 4 insulin dependent diabetic patients experience anxiety 
regarding self-injection. This contributed to the more worrying statistic that nearly 65% of 
type 1 and 2 diabetic patients are not confident in their ability to manage their disease by 
themselves (Korytkowski et al, 2005). This statistic is further emphasized by the fact that 
approximately 20% of children place their injections in and around the same area (Aronson, 
2012). Repeated injections around the same spot has been strongly associated with skin 
thickening around the injection sites. Studies have shown a correlation between increased 
skin thickening and poor glycaemic control, suggesting that the increased thickness around 
injection sites prevent the correct dose of insulin from being administered (Derraik et al, 
2014).  
Due to the drawbacks of hypodermic injection of insulin and lack of suitable alternatives, 
microneedles are drawing attention as an alternative pathway for insulin delivery. 
Microneedles (MN) are narrow needles of the order of microns with lengths up to 1mm 
which can pierce through the stratum corneum, but will not penetrate deep enough into the 
skin to stimulate nerve receptors, making the procedure painless. MNs have already proven 
an attractive medical devices for transdermal delivery for a wide range of active substances 
such as vaccines, proteins, anticancer drugs, oligonucleotides and DNA (Arora et al., 2008, 
Kim et al., 2014). It has been found that MN insertion pain was significantly lowered when 
compared to injection via subcutaneous injection.  
A hindrance in the transdermal delivery of therapeutic proteins is that they are labile 
under unfavourable conditions. Insulin can become denatured due to hydrolytic reaction or 
possibly transformed to components of a higher molecular weight, when delivered through 
transdermal mechanisms (Vimalavathini et al, 2009. Ye et al., 2008). Therefore, to avoid 
issues with insulin stability, surfactants must be added to the formulation, to stabilize the 
structure of the product (Fonte et al., 2012). However, this can present another obstacle as the 
substance added could potentially increase the dissolution time of the formulation, meaning 
insulin is absorbed into systemic circulation at a slower rate.  
This study sought to develop an insulin-polymer solution which can allow the greatest 
uptake of drug onto the microneedle array and rapidly deliver the highest amount of drug into 
the skin. Previous studies have used polymers as insulin stabilizers, due to their quick 
dissolution time within the skin (Chen et al, 2012. Ling et al, 2013). Gelatin is as a potential 
insulin stabilizer due to its biodegradability, biocompatibility, non-immunogenicity and film-
forming ability (Thyagarajapuram et al, 2007). This is ideal for insulin delivery via 
microneedle as it should not interfere with the therapeutic action of the insulin, instigate no 
immune reaction and the film forming properties should allow for easy uptake onto the 
microneedle. Gelatin has been shown to promote transmucosal delivery of insulin by 
increasing the permeability of the drug through epithelial membranes (Seki et al., 2005). This 
evidence justifies the choice of gelatin as an insulin stabilizer. 
Trehalose is established as an excellent protein stabilizer and past studies have shown to 
be uniquely suitable for stabilizing proteins due to its low chemical reactivity, non-reducing 
nature and a high affinity for water molecules. (Kaushik et al, 2003.). However, studies using 
mouse models have found that Trehalose suppresses adipocyte hypertrophy and mitigates 
insulin resistance. This could be cause for concern, as a resistance of the delivered insulin 
would undermine the stabilizing properties of the polymer (Arai et al, 2013). Another 
potential stabilizer analysed is polyvinyl caprolactam±polyvinyl acetate±polyethylene glycol 
graft copolymer (Soluplus®). Various studies have shown Soluplus® to promote fast drug 
release and be used as a solubility enhancer (Homayouni et al., 2014). Soluplus® has 
previously been used to increase the bioavailability through oral drug delivery and has been 
shown to adequately stabilize proteins (Paaver et al., 2014).  
Another potential insulin stabilizer is Poly(2-oxazoline) (POx) where numerous studies 
have shown POx to be a highly efficient drug delivery platform which offers low toxicity, 
low complement activation and has extremely high loading capacities for hydrophobic drugs; 
all of which benefit insulin delivery as a large amount can then be delivered safely without 
becoming denatured (Luxenhofer et al., 2010. Tong et al., 2011). POxylated proteins have 
been shown to better enhance the transport and intracellular delivery of proteins than the 
more conventional method of PEGulated proteins (Luxenhofer et al., 2012).  
The microneedles were coated via inkjet printing as the method has been shown to 
deliver highly uniform, reproducible and accurate coatings at various drug±polymer ratios 
(Uddin, et al, 2015)  
 
2. Materials Methods 
2.1. Materials 
Insulin, from bovine pancreas (Sigma-Aldrich, St Louis, MO) as higher MW model 
macromolecule. Gelatin, (GLN) from porcine skin, Type A, 90-110 Bloom (Sigma-Aldrich, 
St Louis, MO) as stabiliser. Trehalose dehydrate (THL), from Saccharomyces cerevisiae 
(Sigma-Aldrich, St Louis, MO), as stabiliser. Soluplus® (SOL) a co-polymer of polyvinyl 
caprolactame-polyvinyl acetate-polyethylene glycol, (BASF, Minden), as stabilizer. Poly(2-
ethyl-2-oxazoline) (POX) as stabilizer. Phosphate buffer saline (PBS) 0.153 M, prepared 
using: Na2HPO4.12H2O 2.86 g/l (8 mM), KH2PO4 0.2 g/l (1.5 mM), NaCl 8.0 g/l and KCl 
0.19 g/l (2.5 mM).  
 
2.2. Microneedle Fabrication 
Arrays of solid microneedles) were fabricated by cutting needle structures from stainless steel 
sheets (SS 304, 75 mm thick; McMaster-Carr, Atlanta, GA, USA) using an infrared laser 
(Reso- netics Maestro, Nashua, NH, USA). The fabricated arrays consisted of 50 needles per 
cm2 and a needle tip radius of 10µm. Initially, the shape and orientation of the arrays were 
drafted in a CAD file (AutoCAD; Autodesk, Cupertino, CA, USA), by using the laser-control 
software. The laser beam traced the desired shape of the needle, which ablated the metal 
sheet and created the needles in the plane of the sheet. The laser was operated at 1000 Hz at 
an energy density of 20 J/cm2 and required approximately 4 min to cut an array. The metal 
sheet with needles on it was cleaned in hot water (Alconox, White Plains, NY, USA) and 
rinsed with DI water. Each needle was then manually bent at 900 out of the plane of the sheet. 
The needles were electropolished in a bath containing a 6:3:1 mixture by volume of glycerin, 
phosphoric acid, and water (Fisher Scientific, Atlanta, GA, USA) to remove debris. This 
electropolishing process reduced the needle thickness to 50 µm. 
 
2.3 Inkjet printing process for MN coating  
Inkjet printing was performed with a Nanoploter II (Gesim, Germany) where the MNs are 
mounted on a specifically designed holder and positioned at 45° relative to the dispenser (Fig. 
1). The drug/polymer solutions were jetted through a piezodriven dispenser (PicPip 300) onto 
the MN surface in the form of fine droplets of approximately 300 pl. The appropriate 
drug/polymer amounts were coated through various coating cycles. For each coating cycle, 6 
GRWVRIDFRDWLQJIRUPXODWLRQHYHU\ȝPZHUHGLVSHQVHGORQJLWXGLQDOO\ WR WKHD[LVRIHDFK
MN and the process was repeated for 50 jetting cycles to coat the desired amounts. The 
dispenser is a piezoelectric ceramic that is deformed upon voltage appliance, thus ejecting a 
droplet from the nozzle at a speed 1± PV ³GURS RQ GHPDQG´ 'XH WR WKH 01 GHVLJQ D
simple coating algorithm that targets the needle edge was designed. In this algorithm the 
numbers of spots, the spots/needle and the distance per spot can be determined. The operation 
process is controlled by a stroboscope, which controls if the dispenser jets according to the 
desired standard droplet size. Before the coating process starts, the dispenser deposits one 
droplet onto a water sensitive paper producing a dark spot in a yellow background (Fig 1a). 
This is used to determine the exact position of the dispenser. Specifically, an algorithm for 
low ± contrast images detects the spot on the paper and calculated its XY deviation from the 
theoretical position (Fig 1b). Stroboscopic image capture provides real-time analysis of 
pipette performance both before and after sample dispensing. Fig. 1c shows the dispenser 
passing in front of the stroboscope. After the accomplishment of each cycle the dispenser 
passed in front of the oscilloscope to check whether the dispensing was according to the 
standards. The droplet diameter allows estimation of the dispensed volume calculated through 
image analysis. If, for any reason, a sample is not dispensed as instructed (e.g. empty sample 
well), the software logs this and allows for repetition of respective sample printing, thus 
ensuring completion of the task. 
 
2.4. Coating formulations 
Polymers were dissolved in deionized water prior to the addition of the insulin solution. 
Table 1 below shows the different insulin-polymer ratios. For the estimation of insulin-coated 
amounts for each formulations three MN arrays were fully dissolved separately in 20ml of 
phosphate buffer (pH 7.4) and the insulin was determined by HPLC analysis.  
 
2.5. Scanning electron Microscopy (SEM) 
The microneedle arrays were mounted on an aluminium stub by the use of doubled-sided 
carbon adhesive tape. The microneedles were analysed using scanning electron microscope 
(JEOL JSM-5310V, Japan). All un-coated and coated MNs was characterised at low vacuum 
(LV mode) and accelerating voltage (20kV) using tilted angle of 83º. All images were 
captured digitally during analysis.  
 
2.6. Atomic force Microscopy (AFM) 
AFM analysis was performed on tapping mode using an easyscan AFM (Nanosurf, Lielestal, 
Switzerland). Tap 190Al-G cantilevers were used (Budgetsensor, Sofia, Bulgaria).The drive 
amplitude and the relative set point were chosen in a way that the intermittent force between 
WKH RVFLOODWHG WLS DQG WKH VXEVWUDWH ZRXOG EH PLQLPXP DQG WKH VFDQ DUHDV ZDV ȝP 7KH
analysis of the images was performed using the nanoscan software.  
As it was difficult to perform AFM analysis on the microneedle without damaging it, the 
solutions were deposited onto the microneedles substrate by using the nano-plotter and 
placing them on 45 degrees. The number of layers were the same as for the other studies. 
 
2.7. Circular Dichroism (CD) 
Insulin ± polymer films were suspended in 200 µL PBS (pH 7.4) and the far-UV spectra were 
recorded between 200 and 280 nm on a Chirascan CD spectrometer (Applied Photophysics, 
UK) with the lamp supplied with a flow of nitrogen. 50 µL of the solution were added to a 
0.1 mm path-length quartz cuvette (Hellma, UK) and the measurements were carried out at 
20 °C (1 nm bandwidth resolution and 1 s acquisition time). Typically, at least two scans 
were recorded, and baseline and PBS spectra were subtracted from each spectrum. Data were 
processed using Applied Photophysics Chirascan Viewer and Microsoft Excel. The protein 
and polymer concentration spectra were normalised by scaling relative to the magnitude of 
the negative maximum (similar approach was used by Schmidt who normalised the value at 
209 nm) (Schmidt et al, 2014). 
 
2.8. Skin preparation for in-vitro MN testing  
Filter paper was soaked in water and placed in petri dish. A small amount of phosphate buffer 
at 7.4 pH was added. This will prevent a change in the skin cells pH, maintaining it at the 
same level as in the body.  The abdominal area of porcine skin is very fatty, which can 
prevent penetration of microneedles. Fatty areas were removed with scalpel. Porcine skin was 
pinned to polystyrene block and wiped with 70% ethanol. The skin was then cut at 750µm by 
applying the dermatome at an angle of ±45°. The skin was cut at 750µm as the microneedles 
measured 600 in length. This will allow the microneedles to penetrate the skins outer layers 
and deliver the drug directly into the dermis. The thickness of skin was measured by using a 
micrometer after placing a cover slip as a support base. The thickness of the cover slip was 
measured alone followed by the skin and cover slip together; the actual thickness was 
determined by subtracting one measurement from the other. Tissue disks of the required 
dimensions were cut for the Franz diffusion cells using a blade. The skin tissue (750±900 mm 
thick) was placed in PBS (pH 7.4) for 2 h. Padgett Dermatome and dermatome blades were 
purchased from Integra LifeTM Sciences Corporation (PA, USA). 
 
2.9. In-vitro permeability studies by using Franz diffusion cells 
The phosphate buffer (PBS) was maintained at pH 7.4 and filled into the Franz diffusion cells 
(Permegear Inc.).  A fraction collector (Gilson FC 204, Middleton, USA) was attached the 
water bath (Thermofisher scientific, Newington, USA) and PBS was supplied through a 
pump (Minipuls 2, Gilson, Luton, UK). Each cells were calibrate precisely with PBS at a rate 
6-6.5 ml per hour. The receptor arm was sealed with plastic cap and the donor compartments 
were sealed with a cover slip to avoid sample evaporations. The constant temperature of the 
experiment was maintained at 37ºC and an applied skin surface temperature of 32ºC. The 
cells were equilibrated up to 30 minutes before introducing test formulations to the donor 
compartments. The integrity of epidermal sheets was monitored for a while prior to start each 
experimental method. 
The drug coated MN arrays were applied for 30 s onto the skin with an applied force of 7N 
using the TA HD plus texture analyser (Stable micro system, Surrey, UK). Dislodge-ment of 
the MN arrays was prevented using an adhesive tape (3M, UK). Subsequently, the skin 
samples with the inserted MN arrays were mounted in the Franz diffusion cells with the 
stratum corneum on the topside. The drug cumulative release was measured for each 
formulation in triplicates over a 2 hr period with a sample being taken every 10 minutes for 
the first hour and every 30 minutes for the second hour.  
 
2.10 HPLC analysis  
 The amount of insulin present in the receptor fluid was determined using HPLC analysis. An 
Agilent technologies 1200 series HPLC system (AgilentTechnologies, Cheshire, UK) 
equipped with a Phenomenex Jupiter 5u c18 300Å, LC Column (250 x 4.60mm, particle size 
5 µm, Macclesfield, UK) was used. The mobile phase consisted of water with 0.1% TFA and 
acetonitrile with 0.1% TFA (65:35 v/v), with a 1ml/min-1 flow rate (Liu et al., 2012). The 
eluent was monitored with a UV detector at 214nm, the column was equilibrated to 35°C and 
the injection volume was 20 µm. The results were integrated using Chemstation® software. 
The drug amount coated on the microneedle was quantified by placing the microneedle array 
in 10ml of deionised water and sonicating for 10 minutes to dissolve the coating layer. The 
insulin amount present was determined by HPLC analysis.   
 
3. Results and Discussion 
3.1. Jet coating 
In general the quality of the coating depends on the size of the dispenser, the voltage 
applied and the duration of the pulse. Our evaluation showed that tips with 300 pl aqueous 
droplet volume are suitable for microneedles coating. Tips generating smaller volumes (100 
pl) can result in tip clogging. Moreover, a smaller tip cannot dispense such concentrated 
solutions as it requires less viscous solutions. In terms the voltage applied, it has been proved 
that the fluid volume ejected from the dispenser and as a consequence the droplet size is a 
linear function of the voltage (Tekin et al., 2008). An increase in the applied voltage for a 
given coating solution will lead to an increase in the diameter of the droplets. However, an 
increase of pulse duration will result in more complicated and periodic behaviour (Tsai et al, 
2008). Also, increasing the voltage, the ejection velocity of the drop will increase and hence 
the impact of the drop onto the needle surface will be bigger causing splashing. Therefore, it 
was found that the optimal applied voltage and pulse duration during the coating process 
ZHUH 9 DQG ȝVHF UHVSHFWLYHO\ 7KH GURSOHWV KDG D FRQVLVWHQW SDUWLFOH VL]H of 100 - 
120Pm without any satellites as observed from the stroboscope. 
As previously mentioned (Uddin et al.) the distance of the nozzle from the 
microneedle is of the utmost importance. Due to the small generated droplets the dispenser 
must be as close as possible to the surface of microneedles. Therefore, the microneedles were 
positioned at 45o relative to the dispenser. During the process the height of the dispenser 
changes according to the equation below in order to keep the distance between the dispenser 
and the microneedle at a constant value.  
ǻ/ DVLQo    (1) 
:KHUHǻ/LVWKHheight increase of the nozzle from the microneedle after dispensing of each 
droplet and a is the distance of each spot (droplet).  
Fig. 2 illustrates a typical coating of insulin with THL, which is the result of 45 
cycles. As it is clear that the deposited layers are spotted on the microneedle surface without 
any coating on the substrate or droplet satellites. By rotating the MN array it is possible to 
coat both sides of each needle and deposit equal amounts of coating material. Each 
microneedle was coated accurately with 110 s10µg of insulin in order to avoid the 
deposition of bulky layers on the needle surface. As shown in Fig.2 the applied coatings were 
uniform and reproducible without any defects.  On of the main advantages of inkjet printing 
compared to conventional coating techniques is the negligible material losses, high accuracy, 
reproducibility and the easiness of process scale ± up. Ink jetting can be also used to apply 
aqueous or organic solvent coatings in routine manner. Inkjet printing results in a very small 
size of the dispensed droplets and the formation of film layers is rapid due to the fast 
evaporation of the coating medium. 
 
3.2 ± AFM 
AFM has been previously used to investigate the stiffness/roughness of polymeric 
films and the homogeneity/uniformity as well (Salerno et al., 2010). Fig. 3 illustrates the 
topographic image of pure polymers. The studies showed that inkjet printing produced 
smooth polymeric surfaces with SOL demonstrating the best performance (Table 2). When 
insulin was incorporated in the polymeric solutions at very high loadings (50:50 wt/wt) the 
printed layers became rougher, with the exception of the insulin ± POX layers. However, 
even in this occasion the estimated values of the film roughness remained small enough 
demonstrating the formation of smooth layers. In general, the roughness of the coating should 
be as smooth as possible to avoid the removal and consequently deposition of the coating 
layers on the skin during the MN piercing. 
Moreover, all of the inkjet printed insulin ± polymer formulations presented 
homogenous and uniform layers without any phase separation observed.  As previously 
shown the homogeneity of the applied inkjet dispensed layers is a prerequisite to achieve fast 
release of insulin as previous studies shown (Uddin at al. 2015). The AFM analysis was in a 
good agreement with the smooth layers observed in the SEM images. 
 
 
3.3 CD 
In order to evaluate the effect of inkjet dispensing and the formation of thin polymer 
layers where insulin is present at solid state, CD analysis was conducted as shown in Table 3. 
CD is a well known spectroscopic technique that provides valuable information related to 
denaturation and helix coil transformations of insulin. In these studies all MN coated 
formulations were kept at 4oC prior CD evaluation in order to eliminate any possible insulin 
degradation.  As shown in Fig. 5 insulin absorption bands associated with alpha helices and 
ß±sheet are seen at 208 nm and 222 nm respectively (Gopal et al, 2012). The obtained spectra 
are in agreement with previously reported studies especially those representing the alpha-
helical structure of insulin (Patil et al, 2014). These studies demonstrated that the relative 
ellipticity of the 222 nm band with respect to the 208 nm band was between 70 and 90 %. As 
shown in Fig. 6 the insulin/THL and insulin/SOL coatings showed almost identical bands 
with those of the insulin sample (i.e. RI209 ~= RI222) suggesting very good physical stability 
of insulin within the polymer layers. For the insulin/GLN coatings a small minimal shift from 
222nm spectra was observed. This type of shift was identified by Zhang et al., (2010) for 
insulin encapsulated in nanoparticles and are attributed to interference of GLN with insulin 
without however affecting significantly the a-helix/ß ± sheet of the protein.  
In contrast a significant change can be seen for the insulin/POx coatings at the second 
negative maximum at 206, which has completely disappeared. This type of behaviour could 
be related to manipulation or processing conditions, but also on strong molecular interactions 
between the insulin and the polymer (Zhang et al, 2010). This type of interactions can 
effectively lead to some conformational changes, thus exposing hydrophobic areas to outside, 
resulting in reduced solubility and an increased tendency of aggregation. This can also result 
in dissociation of insulin hexamers into monomers and dimers. CD analysis of insulin/POx 
coatings indicates that insulin undergoes one of the aforementioned interactions, which 
requires further investigation.   
 
3.4 Release studies 
To identify which drug stabilizer offers the greatest and most rapid delivery, the 
amount of insulin release from the coated MNs was estimated by using Franz cell diffusion. 
Using Franz cell diffusion a permeant will diffuse from a vehicle in the donor chamber, 
through an artificial or biological membrane into receptor fluid, which will drip into a 
receptor chamber. In this case as the polymer stabilizer dissolves, the insulin will diffuse 
from the microneedle through the porcine skin into the continuously flowing receptor fluid.  
From the results shown in Fig. 7, it is clear that SOL allowed for the most rapid 
release of insulin, with 65% being released within the first 10 min while 95% under 30 min.. 
GLN showed a similar release profile indicating that both GLN and SOL dissolve quickly 
enough for insulin to rapidly delivered into the bloodstream. However POX and THL have a 
poor first release showing that both coating formulations are poorly suited to deliver insulin 
into circulation. POX had an especially poor release delivering with only 42% of insulin after 
30 min, compared to GLN and SOL.  
The long-term usability of microneedles as a form on insulin delivery hinges on the 
convenience of their use and dosage control. Through hypodermic injection, the complete 
dose is delivered within seconds and the insulin may rapidly take effect. Therefore for 
microneedles to become the preferred choice, insulin must be released as quickly as possible. 
Current data suggests that the optimal injection-to-meal (IMI) interval for both type 1 
diabetics is between 20-30 minutes (Müller et al, 2011). Therefore, based on this data it is 
important for the polymer stabilizer to allow the insulin to be absorbed within this time 
frame. The microneedles loaded with the SOL and GLN solutions released over 80% of 
loaded insulin under 30 min, suggesting that both could serve as suitable insulin carriers. 
However, emerging research has downplayed the importance of IMI in type 2 diabetics 
(Müller et al, 2013). For a diabetic patient to achieve optimal blood glucose control, the 
amount of insulin injected must correlate with food intake after injection. Therefore, it is 
important that the entire injected amount of insulin be absorbed into circulation; if even a 
small amount of insulin remains undelivered, it could have a potentially great effect on 
blood-glucose levels (Ma et al, 2006).  After 40 min the microneedle coated with SOL-
insulin released all of the active substance and only a small amount being released outside of 
the optimal IMI. From this it can be concluded that SOL is the best and only real success of 
the experiment, releasing its full amount within an acceptable timeframe.  
Despite its fast initial release, GLN did not release its full amount of loaded insulin. It 
was however only a minor amount, which remained, undelivered and could be attributed to 
the fact that GLN could potentially create a viscous solution in the MN proximity. This 
would eventually slowdown the release rates of insulin. Future rheological studies for 
different GLN grades and also insulin/GLN ratios would lead to further optimization. The CD 
studies revealed a small shift from 222nm in the insulin/GLN coatings. This could potentially 
cause a disassociation of insulin hexamers. An investigation into how strong these 
interactions are would reveal the full effect gelatin exerts   on the insulin molecule.  
The worst performing polymer stabilizer was POX, with a slow release of less than 
half of the loaded insulin. This can be attributed to the conformational changes observed in 
the CD studies. The strong reactions between POX and insulin could have potentially caused 
changes in structure which possibly lead to decreased solubility. Therefore, the POX-Insulin 
complex would not readily dissolve once injected into the skin, meaning a large portion of the 
insulin loaded would not be absorbed into circulation. The slow release of POX can also be 
attributed to the breakdown of insulin hexamers into monomers and dimers will cause the 
insulin molecules to exhibit limited bioavailability after administration (Patil et al, 2014).   
Trehalose also performed poorly in this experiment, with a slow release time and a 
failure to deliver all of its loaded insulin. This result is surprising given THL proven 
capability as an effective protectant (Rodrigues et al, 2008). Further studies into the hydration 
rates of the polymer could help explain this result.  
 4. Conclusions  
Inkjet printing was employed to develop insulin polymeric layers on metal microneedles for 
transdermal layers.  Surface characterization of the printed layers showed homogeneous and 
uniform layers without any defects on the metal surface. Circular dichroism revealed stable 
insulin layers with intact alpha helices and ß±sheets for THL and SOL while possible 
structural configurations were observed for GLN and THL.  Most importantly rapid insulin 
release rates were observed fro SOL and GLN within the first 20 min suggesting that solid-
state insulin delivery via microneedles is feasible.  
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Table 1: Compositions of polymer and insulin solutions  
Formulations Compositions  
(5mg/10ml) 
F1 POX/ Insulin 
F2 GLN/Insulin 
F3 THL/Insulin 
F4 SOL/Insulin 
 
Table 2: Surface roughness of pure polymers and polymer/insulin mixture after jetting with 
inkjet technique. 
Polymers Roughness 
(Sa) nm 
Insulin Coatings Roughness 
(Sa) (nm) 
GLN 1.70 GLN 2.29 
POX 3.40 POX 1.91 
THL 0.48 THL  3.13 
SOL 7.42 SOL 16.9 
 
Table 3 Values obtained from CD analysis for each experiment. Wavelengths of maxima and 
ellipticity relative to negative maxima. 
 Insulin/POX Insulin/GLN Insulin/THL Insulin/SOL Insulin  (pure) 
Negative 
maximum, nm 225 208 209 209 204 
2nd negative 
maximum, nm 
and relative 
ellipticity 
N/A 225, 53.6 % 223, 80.8 % 223, 68.8 % 210, 98.9 % 
ß ± Sheet (222 
nm), relative 
ellipticity 
95.4 % 52.2 % 77.4 % 69.2 % 100 % 
Alpha helix 
(208 nm), 
relative 
ellipticity 
30.7 % 100 % 97.1 % 100 % 91.9 % 
 
 
 
Figures Caption List 
Fig. 1 jet coating of microneedle 
Fig. 1 a) Deposition of the droplet onto the water sensitive paper, b) positioning of the piezo-
dispenser and the MN array for coating of insulin/polymer solutions, c) calculation of the XY 
deviation of the spot from the theoretical value and d) photographic image of the dispenser 
passing in front of the stroboscope during the coating. 
Fig. 2: SEM image of a THL/insulin coated microneedle array. 
Fig. 3: Topographic (left) and phase images of POX(a), GLN(b), THL(c) and  SOL(d) 
produced by their deposition using inkjet dispensing 
Fig. 4: Topographic (left) and phase imaging of dispensed mixtures of POX-insulin (a), 
GLN-insulin (b) THL-insulin (c) and SOL-insulin coating formulations by using inkjet 
dispensing 
Fig. 5:  CD spectra of insulin films rehydrated in PBS (pH 7.4). 
Fig. 6: CD spectra of insulin films and GLN rehydrated in PBS (pH 7.4). 
Fig. 7: in-vitro release profiles for insulin-polymer coating formulations using Franz 
diffusion cells (n=5). 
 
